{"schema_version":"secwatch.filing_event.v1","accession":"0000012208-23-000062","form_type":"8-K","ticker":"BIO","cik":"0000012208","company_name":"BIO-RAD LABORATORIES, INC.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.351947+00:00","generated_at":"2026-06-12T07:20:26.214527+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bio-Rad Q2 net loss $1.16B on investment swings; lowers FY2023 outlook on softer biopharma demand","bullets":["Net sales $681.1M, down 1.4% (0.3% currency-neutral); ex-COVID revenue up 4.6% currency-neutral.","Life Science segment sales $300.2M (-6.9%); ex-COVID growth 4.5% driven by ddPCR/qPCR.","Clinical Diagnostics sales $380.1M (+3.3%); ex-COVID growth 4.8% on diagnostic systems and quality control.","Operating income $89.6M vs $122.9M; net loss $1,162.3M ($39.59/sh) primarily from Sartorius AG fair value changes.","CEO lowers FY2023 expectations due to softer demand from large biopharma and persistent early-stage biotech weakness."],"urls":{"canonical":"https://secwatch.observer/filing/0000012208-23-000062","json":"https://secwatch.observer/filing/0000012208-23-000062.json","markdown":"https://secwatch.observer/filing/0000012208-23-000062.md","text":"https://secwatch.observer/filing/0000012208-23-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/12208/000001220823000062/0000012208-23-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/12208/000001220823000062/bio-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T07:20:26.214527+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1635ae8167021f09fa7d58db4d40616c69d3a88f","claim":"BIO-RAD LABORATORIES, INC. reported the second quarter ended June 30, 2023 results: revenue $681.1 million, net income $1,162.3 million, EPS $39.59 per share. Guidance reaffirmed.","evidence_excerpt":"Second-quarter 2023 net sales were $681.1 million, a decrease of 1.4 percent compared to $691.1 million reported for the second quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220823000062/0000012208-23-000062-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$681.1 million"},{"label":"Net income","value":"$1,162.3 million"},{"label":"EPS","value":"$39.59 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}